The new double-headed antibody targets both CD3 and BCMA, a target that already features in approved therapies for ... autoleucel – now heading for an FDA verdict by 28 February after a three ...
Hosted on MSN12mon
Johnson & Johnson wins FDA nod for Carvykti label expansionJohnson & Johnson (NYSE:JNJ) has received FDA approval to expand the current labeling ... Accordingly, the treatment-targeting B-cell maturation antigen (BCMA) will be indicated in the U.S ...
Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies ... and Pfizer’s Elrexfio (elranatamab), which are already FDA-approved in this indication, and the jury is out ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor ... that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated ...
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback